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Cancer is one of the most serious problems in
contemporary medicine. According to statistics,
breast cancer is the most frequently diagnosed
type of cancer among women in many countries.
Despite widely spread breast cancer prevention
programs, the number of diagnosed cases is
continuously increasing at a rate of 1% per year
[Beardsley, 1994; Special Raport, 1993]. The
pathogenesis of this disease is still unknown.
Considering the complex etiology of breast
cancers, two basic groups of risk factors have
been distinguished on the basis of social and
genetic criteria [Davis and Bradlow, 1995;
Special Raport, 1993]. The first group includes
the impact of sex hormones and certain
chemical compounds (the so called social
xenoestrogens), the reproductive model,
geographical factors, diet, socioeconomic factor,
alcohol consumption and smoking. The other
group encompasses risk factors of a hereditary
nature which have been under intense
investigation in the last few years. This resulted
in the discovery of genes whose defects and the
resulting expression disorders have an impact
on the development of breast cancer. This
achievement is undoubtedly the effect of an
enormous development in genetic engineering
and molecular biology.
The results of epidemiological research
which has been carried out for several years in
more than 200 American families with multiple
history of breast orland ovarian cancer (often in
young people) suggested that the susceptibility
to this disease was· of hereditary nature [Collins,
1996]. The conjectures of the epidemiologists
have been confirmed by genetic research
performed during the last two years.
After four years of investigations, the
first of the two known genes predisposing to
breast and ovarian cancer was finally identified
in October 1994 by M.H. Skolniyk et al. from
University of Utah and labeled BCRA1 (BReast
Cancer1) [Miki et ai, 1994].
Fifteen months later the second gene
related to the hereditary forms of breast and
ovarian cancers was identified simultaneously by
two independent teams from Great Britain and
America and it was labeled BRCA2 (BReast
Cancer2) [Marx, 1996; Miki et ai, 1994].
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Altogether, the defects in these genes are
responsible for 80-90% of hereditary breast
cancer cases [Szabo and King, 1995]. The
remaining genetically conditioned cases can be
attributed to genes such as p53, AT (ataxia
telangiectasia), androgen receptor gene and the
still undiscovered BRCA3 and BRCA4. Although
research on these genes is at an infant stage,
biologists, genetic engineers and doctors are
already raising questions on how women
carrying the defective genes can benefit from
these discoveries.
The highest morbidity and mortality rates
are observed among white women in highly
developed countries. The cumulative risk of
developing cancer by the age of 85 is estimated
at 12,6% which means that in terms of statistics
one in every 8 women will be affected.
Hereditary cancer constitutes 5-10% of all
diagnosed cases. Conjugate analysis, carried
out in families with a family history of breast
cancer, revealed that 45% of breast cancer
cases were related to the mutation of BRCA1 in
families with multiple cases of breast cancer. In
families where breast cancer as well as ovarian
cancer were observed, the rate was 75%.
Carriers of mutations in any of the genes are at
a higher risk of developing cancer at some point
in their lives. Among women with BRCA1
mutations the cumulative risk of breast cancer
rises to 85% and cumulative risk of ovarian
cancer reaches 50%. Among male carriers of
the mutation, the risk of acquiring prostate
cancer rises threefold while the risk of colon
cancer rises four times in men as well as in
women. The other gene, BRCA2 is related to the
existence of hereditary forms of breast cancer in
men, among whom the disease occurs 100
times less often. The risk of developing breast
cancer in male carriers of BCRA1 mutations by
the age of 70 is estimated at 6%. Mutations in
the gene have been found in 15% of all
diagnosed cases of breast cancer among men.
Defects in BCRA2 are also related to greater
susceptibility to prostate and larynx cancer
[Szabo and King, 1995].
According to early data on the frequency
of BRCA 1 mutations in the general population,
1 in 200 women on average is a carrier of a
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defected gene [Nowak, 1994]. In the light of the
latest research data published in January 1996,
it seems, that in some cases this value has been
overestimated and in other cases it was
underestimated. Research conducted among
jewish families showed that a mutation known
as 185deiAG (dinucleotide deletion in position
185 in the 2 exon) is frequently found among this
population [Friedman et ai, 1995]. It occurs in 1%
of Jewish women that is at a rate of 1 in every
107 women. A corresponding rate for women
eXcluding the jewish ethnic group was
estimated as 1:833 [Collins, 1996]. According to
available data, the frequency of mutations in the
BRCA1 gene is conditioned ethnically, the fact
which must be taken into account when defining
the frequency of mutations in a given population.
We must also remember that not all the
mutations in this gene have already been
identified. The number of mutations will probably
grow as was the case with other preViously
investigated genes such as p53. This fact will
significantly influence the real value of the
mutation prevalence rate.
The discovery of genes predisposing to
breast cancer, the progress in screening
techniques and the development of breast
cancer prevention have all contributed to the
early detection of cancer when the chances for
cure are still high. lfis understandable thus, that
more and more women seek information on their
individual breast cancer risk. This is especially
important for women with a family history of
breast cancer [Hoskins et ai, 1995].
Recently, a few models for predicting
breast cancer risk have been developed [Claus
et al]. Risk evaluation guidelines, proposed by
E.B.Claus et ai, consider the number and
configuration of affected family members and
their age at onset, based on the assumption that
the gene is transmitted as an autosomal
dominant trait. The guidelines have been
prepared on the basis of data coming from 4,730
patients with histologically confirmed breast
cancer in the age group from 20 to 54 and 4,688
people in the control group. The data include
information on cases of breast cancer in
mothers and sisters of the affected women and
the controls. The evaluation of risk on the basis
of E.B.Claus's model pertains only to women
belonging to the high risk group, that is those
with at least one first-degree female relative
suffering from breast cancer. Predictions based
on E.B. Claus's model help to define breast
cancer risk depending on the age of a woman
with one or two relatives with breast cancer
according to the relative's age at disease onset.
Other models of breast cancer risk evaluation
have also been developed; in addition to family
history and age at diagnosis these models
involve other factors such as age at primiparity,
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the number of undergone breast biopsies and
age at menopause.
Any attempt to evaluate breast cancer
risk is bound to be erroneous. This is due to the
fact that because of the high morbidity rate in
general population, a large number of women
have at least one relative suffering from breast
cancer which is not conjugated with the mutation
in BRCA1 and BRCA2 genes. Nevertheless, the
basis for evaluation of breast cancer risk in a
particular patient is a properly gathered and well
documented family history, according to which
the pedigree analysis can be performed.
Investigations aiming at the localization
and identification of BRCA1· and BRCA2 genes
and identification of their mutations were based
on families in which numerous cases of breast
and ovarian cancer had been well documented
for at least three generations. In such families
the evaluation of risk is relatively easy. It must
be remembered, however, that because in most
cases we deal with families in which a detailed
interviews (the base of risk evaluation) could not
be performed, false positive or false negative
results can be obtained. Furthermore, not all
carriers of mutations in BRCA1 and BRCA2
genes present a family history of breast cancer
and that is Why not all of them are included in the
high risk group [Hoskins et ai, 1995; Langston et
ai, 1996].
Both of the discovered genes are very
big - BRCA1 is almost ten times longer than the
average human gene. The identified mutations
(over 100 in the case of BRCA1 and 11 in the
case of BRCA2) are dispersed, that means they
occur along the entire sequence of the gene.
Only 30% of the known mutations in BRCA1
were found in at least two examined families and
only two, 185deiAG and 5382insC, in over 25
analyzed families [Collins, 1996]. It is also hard
to relate a particular mutation to a phenotype
effect it causes. According to current estimates,
a woman with a mutation in BRCA1 has a
lifetime risk of developing breast cancer equal to
85%. In reality the probability of developing
cancer depends on the type of mutation carried
by the patient. For the time being, the discovery
of defective BRCA1 or BRCA2 genes allows us
only to inform the patient, that she exhibits a
higher susceptibility to breast cancer and/or
ovarian cancer. However, we cannot say when
the disease will occur and whether it will occur at
all. At the same time, the woman who is aware
of the high risk of breast cancer has no other
possibilities of preventing the development of the
disease apart from frequent diagnostic
examinations which lead to early diagnosis.
Research related to the identification of
mutations uses techniques based on DNA
analysis. Unfortunately none of the current
techniques has a 100% sensitivity. Taking into
Rep. Praet. Oneol. 1 (1) 1996
Godlewski et al.: BRCA1 and BRCA2 Genes
account the size of the gene as well as the
dispersed nature of the mutation, it is
understandable that the preparation of a reliable
and relatively simple test encounters technical
and financial problems. In the United States
attempts to devise a test for detecting BRCA1
defects were undertaken by the Myriad Genetics
Company. The Marag Genetics holds the license
for BRCA1 gene and its utilization in medical
diagnostics and are currently trying to obtain the
license for BRCA2 gene [Leutwayler, 1995;
Marx, 1996]. In the light of the facts mentioned
above, a large group of oncologists and
molecular biologists claim that, at present,
research on the defects in the BRCA1 and
BRCA2 genes should not be used as a
diagnostic test for detecting asymptomatic
susceptibility to breast or ovarian cancer.
The discovery of BRCA1 and BRCA2
gives hope for a better understanding of the
molecular nature of hereditary breast cancer and
for the introduction of a test to detect defects in
these genes. Concurrently, there occurred
questions and problems of not only medical or
biological nature but also legal and ethical
a$pects. Advocates of tests claim that patients
have the right to know whether they are at a high
risk of breast cancer and it is unethical to
withhold the information from them. Opponents
claim that it is too early to introduce the tests,
which can only be treated as scientific
instruments, especially that, at the present state
of knowledge, the interpretation of results is
inconclusive.
Rep. Pract. Oncol. 1 (1) 1996
REFERENCES
1. Beaq;:Isley T.: Wojna weictZ trwa. Swiat Nauki,
Marzec 1994, 68 - 77.
2. Claus E. et al.:
3. Collins F.: BRCA1 Lots of Mutations, Lots of
Dilemmas. The New England Journal of Medicine.
1996,334,186 -188.
4. Davis D. and Bradlow H.: Estrogeny Srodowiskowe
a rak piersi. Swiat Nauki, Grudzien 1995, 76 - 81.
5. Friedman L. et al.: Novel Inherited Mutations and
Variable Expressivity of BRCA1 Alleles, Including the
Founder Mutation 185deiAG in Ashkenazi Jewish
Families. Am. J. Hum. Genet. 1995, 57, 1284 - 1297.
6. Hoskins K. et. al.: Assessment and Counseling for
Women With a Family History of Breast Cancer.
JAMA, 1995, 273, 577 - 585.
7. Langston A. et al.: BRCA1 Mutations in a
Population - Based Sample of Young Women With
Breast Cancer. The New England Journal of
Medicine, 1996, 334, 137 - 142.
8. Leutwayler K.: BRCA1 i rak piersi. Swiat Nauki,
Luty 1995,12 - 14.
9. Marx J.: A Second Breast Cancer Susceptibility
Gene Is Found. Science, 1996,271,30- 31. .
10. Miki Y.et al.: A Strong Candidate for the Breast
and Ovarian Cancer Susceptibility Gene BRCA1.
Seince, 1994, 266, 66 - 71.
11. Nowak R.: Breast Cancer Gene Offers Surprises.
Science. 1994,265,1796 - 1799.
12. Special Raport: The Politics of Breast Cancer.
Science, 1993,259,618.
13. Szabo C. and King M.e.: Inherited Breast and
Ovarian Cancer. Human Molecular Genetics, 1995,4,
1811 -1817.
14. Wooster R. et. al.: Identyfication of the Breast
Cancer Susceptibility Gene 6RCA2. Nature, 1996,
271,30 - 31.
55
